X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.4 39.6 36.3% View Chart
P/BV x 3.8 3.3 115.4% View Chart
Dividend Yield % 0.3 0.7 43.0%  

Financials

 GLENMARK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
GLENMARK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9932,095 47.4%   
Low Rs7291,025 71.2%   
Sales per share (Unadj.) Rs325.5492.8 66.1%  
Earnings per share (Unadj.) Rs39.372.6 54.2%  
Cash flow per share (Unadj.) Rs48.794.7 51.4%  
Dividends per share (Unadj.) Rs2.0021.00 9.5%  
Dividend yield (eoy) %0.21.3 17.3%  
Book value per share (Unadj.) Rs159.2862.5 18.5%  
Shares outstanding (eoy) m282.17172.56 163.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.2 83.6%   
Avg P/E ratio x21.921.5 101.9%  
P/CF ratio (eoy) x17.716.5 107.4%  
Price / Book Value ratio x5.41.8 299.0%  
Dividend payout %5.128.9 17.6%   
Avg Mkt Cap Rs m242,991269,194 90.3%   
No. of employees `00013.04.0 323.1%   
Total wages/salary Rs m16,40817,939 91.5%   
Avg. sales/employee Rs Th7,083.921,190.3 33.4%   
Avg. wages/employee Rs Th1,265.44,470.1 28.3%   
Avg. net profit/employee Rs Th855.13,120.0 27.4%   
INCOME DATA
Net Sales Rs m91,85785,037 108.0%  
Other income Rs m3742,338 16.0%   
Total revenues Rs m92,23087,374 105.6%   
Gross profit Rs m20,36734,991 58.2%  
Depreciation Rs m2,6443,817 69.3%   
Interest Rs m2,37320,310 11.7%   
Profit before tax Rs m15,72413,202 119.1%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-100 813.6%   
Tax Rs m3,8272,281 167.8%   
Profit after tax Rs m11,08812,520 88.6%  
Gross profit margin %22.241.1 53.9%  
Effective tax rate %24.317.3 140.9%   
Net profit margin %12.114.7 82.0%  
BALANCE SHEET DATA
Current assets Rs m68,74687,590 78.5%   
Current liabilities Rs m27,027185,578 14.6%   
Net working cap to sales %45.4-115.2 -39.4%  
Current ratio x2.50.5 538.9%  
Inventory Days Days8531 273.9%  
Debtors Days Days9648 200.9%  
Net fixed assets Rs m24,132108,523 22.2%   
Share capital Rs m282345 81.8%   
"Free" reserves Rs m44,643148,481 30.1%   
Net worth Rs m44,925148,826 30.2%   
Long term debt Rs m45,363144,957 31.3%   
Total assets Rs m117,639482,394 24.4%  
Interest coverage x7.61.7 462.1%   
Debt to equity ratio x1.01.0 103.7%  
Sales to assets ratio x0.80.2 443.0%   
Return on assets %11.46.8 168.1%  
Return on equity %24.78.4 293.4%  
Return on capital %19.112.0 160.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,15215,001 374.3%   
Fx outflow Rs m8,0845,150 157.0%   
Net fx Rs m48,0689,851 487.9%   
CASH FLOW
From Operations Rs m6,574-100,393 -6.5%  
From Investments Rs m-7,124-24,202 29.4%  
From Financial Activity Rs m5,432135,705 4.0%  
Net Cashflow Rs m1,99211,110 17.9%  

Share Holding

Indian Promoters % 48.3 52.9 91.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.0 172.5%  
FIIs % 34.4 26.6 129.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   56,727 93,274 60.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 24, 2018 09:23 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS